Hospital
Hugh Chatham Memorial Hospital INC
Hugh Chatham Memorial Hospital INC was paid $9.40M by Medicaid between Jan 2018 and Dec 2024, across 123 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoHUGH CHATHAM MEMORIAL HOSPITAL INC
ELKIN, NC 28621
ELKIN, NC 28621
33aNPI1942361308assigned 12/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.40M
24GClaims240,458
24DCodes billed123
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#53 of 92
Median peer was paid$11.47M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 42,271 | $1.14M | |
| 2019 | 45,057 | $1.25M | |
| 2020 | 25,329 | $519K | |
| 2021 | 24,945 | $957K | |
| 2022 | 35,306 | $1.73M | |
| 2023 | 34,178 | $1.92M | |
| 2024incomplete | 33,372 | $1.89M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 15,565 | 14,190 | $2.39M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 15,397 | 14,290 | $1.72M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 17% | 10,266 | 9,252 | $1.61M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.5% | 27,196 | 24,862 | $612K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.3% | 22,261 | 20,531 | $499K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 2,252 | 1,998 | $402K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 4,577 | 4,175 | $178K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 6,596 | 5,800 | $169K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 5,532 | 5,115 | $163K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.6% | 4,589 | 4,354 | $150K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 486 | 448 | $138K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 137 | 122 | $124K |
111 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 1,881 | $114K |
| 80053 | Comprehensive metabolic panel | 1.2% | 16,741 | $114K |
| J3490 | Unclassified drugs | 1.1% | 36,881 | $107K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 16,819 | $104K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,796 | $92K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,665 | $67K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,793 | $55K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 198 | $42K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 600 | $39K |
| 99205 | Prolong outpt/office vis | <1% | 682 | $36K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,607 | $31K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 210 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 469 | $30K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,125 | $29K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,626 | $27K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 543 | $23K |
| G0378 | Hospital observation service, per hour | <1% | 531 | $22K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 458 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,026 | $20K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,424 | $19K |
| 81001 | <1% | 6,547 | $18K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 57 | $17K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 660 | $14K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,039 | $12K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 238 | $12K |
| 87631 | <1% | 141 | $11K | |
| 83690 | <1% | 1,678 | $10K | |
| 84484 | <1% | 1,492 | $8K | |
| 84703 | <1% | 1,102 | $8K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 33 | $8K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 393 | $8K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 321 | $7K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 355 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 560 | $7K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 193 | $6K |
| 94060 | <1% | 94 | $6K | |
| 43249 | <1% | 46 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,189 | $5K |
| 0001A | <1% | 109 | $3K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 46 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 100 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 380 | $3K |
| 0002A | <1% | 89 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 281 | $3K |
| 0012A | <1% | 45 | $2K | |
| 82550 | <1% | 827 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 513 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 40 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 13 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 278 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 52 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 57 | $1K |
| 0011A | <1% | 44 | $1K | |
| 83735 | <1% | 229 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,019 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 55 | $1K |
| 76801 | <1% | 29 | $961.72 | |
| 94760 | <1% | 91 | $915.04 | |
| 85730 | <1% | 252 | $911.59 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $894.40 |
| 20610 | <1% | 40 | $889.71 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 25 | $865.89 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 25 | $849.87 |
| 94729 | <1% | 24 | $841.50 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 28 | $790.97 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 232 | $770.78 |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 35 | $755.40 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 27 | $701.51 |
| 85610 | <1% | 260 | $598.29 | |
| 80061 | Lipid panel | <1% | 43 | $507.30 |
| 87807 | <1% | 46 | $414.12 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16 | $410.27 |
| 87070 | <1% | 39 | $365.33 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 116 | $352.60 |
| 90688 | <1% | 96 | $326.42 | |
| 81003 | <1% | 147 | $289.40 | |
| A4606 | Oxygen probe for use with oximeter device, replacement | <1% | 16 | $283.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 31 | $277.59 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 219 | $259.25 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 16 | $248.24 |
| 94726 | <1% | 12 | $245.66 | |
| 82607 | <1% | 18 | $236.36 | |
| 82570 | <1% | 104 | $231.45 | |
| 86850 | <1% | 14 | $223.47 | |
| 94010 | <1% | 15 | $203.92 | |
| 85027 | <1% | 47 | $192.19 | |
| 83880 | <1% | 14 | $172.02 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12 | $169.42 |
| 94618 | <1% | 13 | $159.41 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 193 | $137.36 |
| 83605 | <1% | 20 | $104.80 | |
| 82150 | <1% | 12 | $80.79 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 131 | $77.36 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 65 | $69.38 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 42 | $49.42 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 16 | $37.91 |
| 86705 | <1% | 12 | $32.63 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 28 | $20.00 |
| 86704 | <1% | 12 | $15.81 | |
| 86706 | <1% | 12 | $14.65 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 25 | $14.45 |
| 87340 | <1% | 12 | $12.82 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 15 | $11.35 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 31 | $2.31 |
| 91300 | 0% | 283 | $0.00 | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 15 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 13 | $0.00 |
| 80320 | 0% | 21 | $0.00 | |
| 91301 | 0% | 116 | $0.00 | |
| 87581 | 0% | 13 | $0.00 | |
| 87486 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTRIPPEL, DONALD (CFO)
| Provider | Location | Paid |
|---|---|---|
| Hugh Chatham Memorial Hospital, INC | Elkin, NC | $273K |
| Hugh Chatham Memorial Hospital | Jonesville, NC | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.